News >

FDA Approves Lorlatinib for ALK+ NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Nov 02, 2018

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs).

The accelerated approval of lorlatinib in this setting is contingent on the results of a confirmatory trial.
Lorlatinib prescribing information. FDA. Accessed November 2, 2018. https://bit.ly/2P6uini.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x